



Proteomics International

LABORATORIES LTD

ASX release

15 February 2023

ASX code: PIQ

Proteomics International and Apacor extend agreement for exclusive distribution of PromarkerD in Britain

- **Apacor to continue as the exclusive distributor for PromarkerD in Great Britain (England, Scotland and Wales) for a minimum term of five years**
- **The agreement extension follows major milestones, including the UK's National Institute for Health and Care Excellence (NICE) publication on PromarkerD**
- **Estimated 4.8 million people live with diabetes in Britain and the UK's National Health Service (NHS) spends over £10 billion per year on diabetes**

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) announces it has extended its distribution agreement with medical diagnostics company Apacor Limited to bring its PromarkerD predictive test for diabetic kidney disease to patients in England, Scotland and Wales.

Proteomics International commenced working with Apacor in November 2021 and initially signed a two year licence agreement [ASX: 23 November 2021]. Since then, several key milestones have been achieved, notably including PromarkerD being registered for use with the UK Medicines & Healthcare products Regulatory Agency, and the publication of National Institute for Health and Care Excellence (NICE) advice on PromarkerD [ASX: 14 December 2022].

Based on this success Proteomics International and Apacor wished to extend the relationship and have agreed to an additional five year term. Both parties are now working towards the inclusion of PromarkerD in the NICE Guidelines and engaging with the NHS Supply Chain Tender process as part of the commercial roll-out of the test in the UK. The Company will provide timelines for these processes when known.

In the United Kingdom an estimated 4.8 million people, or seven per cent of the population, live with type 2 diabetes¹. The UK's National Health Service spends at least £10 billion per year on diabetes, equivalent to 10 per cent of its budget².

Apacor Managing Director Anthony Bellm said he was excited by the feedback they were seeing for PromarkerD and being able to partner with Proteomics International to bring the test to the UK.

"This world-first test offers huge benefits for the growing number of people living with diabetes in Great Britain, as well as significant savings to the NHS," he said. "The test will support doctors in providing early treatment options for high-risk patients, while avoiding unnecessary interventions for patients who are predicted to be at low risk of a decline in kidney function."

The updated distribution agreement provides Apacor Limited with the exclusive right to sell the immunoassay version of the PromarkerD test in England, Scotland and Wales. The initial term of the

¹ www.diabetes.org.uk

² Diabetes in the UK: 2019 (Diabet Med. 2020; doi/10.1111/dme.14225)

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

updated agreement with Apacor expires on 31 January 2028, and is extendable for additional periods of three years by mutual agreement.

Proteomics International will receive payment for each PromarkerD kit sold. Both parties have the right to terminate the agreement with immediate effect upon the breach of any material terms of the agreement. The agreement is also subject to the standard terms, conditions, and warranties typical of a contract of this type. Further details of the licence agreement are commercially sensitive and remain confidential. As for any novel test, market penetration cannot be predicted accurately, hence for the new market it is not possible to quantify the financial impact on Proteomics International in any given timeframe.

Proteomics International Managing Director Dr Richard Lipscombe said, *“Apacor are proving to be an invaluable partner for creating greater awareness of PromarkerD in the UK. They have 30 years of experience in medical and analytical diagnostics and we've been impressed by their skills, experience and network, especially their strong relationships with government and professional healthcare bodies across the UK.”*

Proteomics International and Apacor have also entered into discussions for extending their relationship into selected countries in continental Europe.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

About PromarkerD (www.PromarkerD.com)

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique ‘fingerprint’ of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: www.PromarkerD.com/product

About Apacor Limited (www.apacor.com)

Apacor (Wokingham, UK) develops and markets practical, cost-effective solutions in the field of medical diagnostics, supplying innovative products to laboratories across the world. Apacor excels in developing quality solutions to suit its customer’s every requirement, and with 30 years experience, it continues to push new ground-breaking ideas to global markets.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com